Table 2 Univariate analyses of risk factors for 30-day crude mortality of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with cefepime
Variables | Deceaseda | Surviveda | Univariate |
|---|---|---|---|
n = 33 | n = 57 | p | |
Demographic parameters | |||
Age, year | 71.5 (12.7) | 64.1 (15.1) | 0.028 |
Male gender | 21 (63.6) | 28 (49.1) | 0.183 |
Concomitant diseases | |||
Diabetes mellitus | 9 (27.3) | 20 (35.1) | 0.445 |
Severe renal impairment | 13 (39.4) | 15 (26.3) | 0.197 |
Liver cirrhosis | 4 (12.1) | 6 (10.5) | 1.000 |
Chronic pulmonary disease | 4 (12.1) | 4 (7.0) | 0.458 |
Cerebral vascular accident | 8 (24.2) | 11 (19.3) | 0.580 |
Solid organ malignancy | 17 (51.5) | 22 (38.6) | 0.233 |
Haematological malignancy | 4 (12.1) | 12 (21.1) | 0.394 |
Autoimmune disease | 2 (6.1) | 3 (5.3) | 1.000 |
Clinical conditions | |||
Time interval between admission and occurrence of bacteremia, day | 31.8 (34.6) | 18.3 (33.6) | 0.019 |
Central venous catheter use | 27 (81.8) | 41 (71.9) | 0.293 |
Patients’ severity | |||
APACHE II score | 23.9 (5.5) | 21.0 (6.1) | 0.091 |
Intensive care unit stay | 18 (54.5) | 11 (19.3) | 0.001 |
Severe sepsis or septic shock | 12 (36.4) | 9 (15.8) | 0.038 |
Neutropenia | 7 (21.2) | 11 (19.3) | 0.827 |
Source of bacteremia | |||
Primary bacteremia | 11 (33.3) | 27 (47.4) | 0.194 |
Lower respiratory tract | 16 (48.5) | 11 (19.3) | 0.004 |
Urinary tract | 1 (3.0) | 6 (10.5) | 0.416 |
Skin and skin structure | 1 (3.0) | 1 (1.8) | 1.000 |
CABSI | 3 (9.1) | 9 (15.8) | 0.524 |
Intra-abdominal site | 5 (15.2) | 5 (8.8) | 0.488 |
Microbiology | |||
MIC ≥4 mg/L | 13 (39.4) | 4 (7.0) | <0.001 |
Treatment | |||
Use of maximum cefepime dose | 15 (45.5) | 45 (78.9) | 0.001 |
Treatment duration | 14.7 (7.2) | 17.5 (6.8) | 0.062 |
Remove catheter or operation | 2 (6.1) | 6 (10.5) | 0.705 |